News

March 23, 2016March 23, 2016

Trinnovate Invests Heavily in VisionGate’s Lung Cancer Clinical Trials

Lung Cancer, News

Trinnovate Ventures recently announced it is partnering with VisionGate, a Phoenix-based company dedicated to improving diagnosis and treatment for lung cancer, to support the clinical trial programs for VisionGate’s LuCED (a ... Read more

March 23, 2016February 1, 2019

In PAH Patients, Low Activity Levels May Lead to Fatigue, Little Energy, Study Shows

News, Pulmonary Hypertension

More than 90 percent of patients with pulmonary arterial hypertension (PAH) report fatigue, but it has not been known if fatigue has an impact on physical activity in these patients. ... Read more

March 23, 2016May 13, 2016

Laurent Pharma to Prepare Phase 2 Trial for Cystic Fibrosis on Heels of New Financing Round

Cystic Fibrosis, News

Montreal-based Laurent Pharmaceuticals recently announced the closing of a financing round, led by new investor Cystic Fibrosis Canada. The round included existing investors such as Aligo Innovation LP and Anges Quebec, and ... Read more

March 22, 2016March 22, 2016

ProMetic’s Scleroderma Treatment PBI-4050 to Enter Phase 2 Clinical Trial

Idiopathic Pulmonary Fibrosis, News, Scleroderma

ProMetic Life Sciences recently announced the initiation of a Phase 2 clinical trial on PBI-4050 for the treatment of scleroderma, a chronic connective tissue disease for which there is currently ... Read more

March 22, 2016March 22, 2016

Xalkori (Crizotinib), for Certain Non-Small Cell Lung Cancers, Gets FDA New Drug Application Approval

Lung Cancer, News

Pfizer’s supplemental new drug application for Xalkori (crizotinib) has been approved by the U.S. FDA for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC). The drug is also ... Read more

March 22, 2016May 13, 2016

FDA Designation to Speed Testing of Inhaled Antibiotic, Levofloxacin, to Treat Lung Infections

Bronchiectasis, Cystic Fibrosis, News

Raptor Pharmaceutical Corp. announced that its proprietary inhaled levofloxacin, MP-376, has been given Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration (FDA) to treat three specific indications: ... Read more

March 21, 2016March 21, 2016

Experts Recommend Zephyr EBV as Only Minimally Invasive Emphysema Treatment for Use Outside Clinical Trials

Emphysema, News

Pulmonx, based in Redwood City, California, recently announced the publication of recommendations from a panel of experts offering broad guidance regarding selection of therapies for patients with advanced emphysema. The panel recommended that only ... Read more

March 21, 2016May 13, 2016

Lung Infections in Cystic Fibrosis Found From Airborne Bacteria Triggering Fungal Growth

Cystic Fibrosis, News

According to new research, volatile compounds released by a bacterial pathogen called Pseudomonas aeruginosa can trigger the growth of a fungal pathogen often found in cystic fibrosis (CF) patients. This is ... Read more

March 18, 2016March 18, 2016

Verona Pharma Reports Positive Early Trial Data for its CF, COPD Lead Drug Candidate

Cystic Fibrosis, News

Verona Pharma recently announced positive top-line results from a Phase 2a dose-finding clinical trial using its novel lead drug nebulized formulation of RPL554, a first-in-class inhaled drug under development for ... Read more

March 18, 2016March 18, 2016

Lung and Other Cancers Now Part of Electronic Health Records Accessed by Via Pathways

Lung Cancer, News

Flatiron Health and Via Oncology recently announced that Via Pathways, a tool to streamline workflow and patient care, has added a number of cancers — non-small cell and small-cell lung, rectal mesothelioma, prostate, breast, colon, and multiple ... Read more